Moore Paul Andrew — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Moore Paul Andrew is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $721K.
Profile
Paul Andrew Moore is the Chief Scientific Officer of Zymeworks Inc., a clinical-stage biopharmaceutical company focused on multifunctional biotherapeutics. In this role, he leads Zymeworks' scientific strategy and development efforts for its pipeline, including zanidatamab, a HER2-targeted bispecific antibody in clinical trials. The SEC filing context (CIK 0001938192, most recent filing date 2026-01-06) shows his insider status with no reported purchases or sales in that period.
Role
Insider
Notability
40/100
Board memberships
Zymeworks Inc.
Awards & honors
Led scientific strategy for Zymeworks' biotherapeutics programs
Overseeing development efforts for zanidatamab, a HER2-targeted bispecific antibody
Paul Andrew Moore is the Chief Scientific Officer of Zymeworks Inc., a clinical-stage biopharmaceutical company focused on multifunctional biotherapeutics. In this role, he leads Zymeworks' scientific strategy and development efforts for its pipeline, including zanidatamab, a HER2-targeted bispecific antibody in clinical trials. The SEC filing context (CIK 0001938192, most rece…
Has Moore Paul Andrew been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($721K) across all tracked filings.
Where can I see all of Moore Paul Andrew's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
